Skip to content

Archer Aviation ACHR Business Segments — Other research and development expense

Similar metrics at other companies

Veracyte logo
VCYTReportable Segment — Other research and development expenses
$5.46M+201%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%
Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Powell Industries logo
POWLReportable Segment — Research and development expenses
$4.29M+56.2%
Globus Medical logo
GMEDReportable Segment — Other Research and Development Expense
$9.17M+20.2%

Other financials

Income statement

See full
Revenue$1.6M
Gross profit$300.0K
Operating income-$254.6M-76.8%
Net income-$217.7M-133%
EPS (diluted)-$0.28-64.7%

Balance sheet

See full
Cash & equivalents$958.4M-7.6%
Total debt$121.8M+55.6%
Total equity$2.1B+106%
Total assets$2.3B+91.2%

Cash flow

See full
Operating cash flow-$149.1M-57.6%
CapEx$32.6M+226%
Free cash flow-$181.7M-73.7%

Valuation

See full
Market cap$4.01B+0.5%

Returns & leverage

See full
Return on equity-48%-12.4pp
Debt / equity0.1×0.0×
Current ratio18.1×+2.3×

Where this comes from

Reported directly by Archer Aviation in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The official record: Archer Aviation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Archer Aviation's business segments — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Archer Aviation's business segments — other research and development expense?
Archer Aviation (ACHR) reported business segments — other research and development expense of $133.3M in Q1 2026.
What does business segments — other research and development expense mean?
This represents secondary or miscellaneous research and development expenditures not captured in primary R&D line items. It provides visibility into the broader scope of innovation spending required to maintain a competitive technological edge.